Table 5.
Cost and effectiveness data derived by Monte Carlo simulation with associated probabilities. All other non-reference strategies were dominated
| Treatment strategy | Cost (£1000s) | Incremental cost (£1000s) | Effectiveness (QALYs) | Incremental effectiveness (QALYs) | Incremental cost effectiveness ratio (£/QALY) | Probability of being cost effective at set willingness to pay threshold* | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| £5000 | £10 000 | £20 000 | £40 000 | £80 000 | ||||||
| Non-dominated strategies | ||||||||||
| Diathermy vaporisation | 380 775 | 0 | 917 082 | 0 | N/A | 0.82 | 0.03 | 0 | 0 | 0 |
| Holmium laser enucleation | 400 550 | 19 775 | 919 656 | 2574 | 7682 | 0.14 | 0.37 | 0.11 | 0.01 | 0 |
| Diathermy vaporisation + holmium enucleation | 413 713 | 13 163 | 921 041 | 1385 | 9505 | 0 | 0.57 | 0.85 | 0.80 | 0.49 |
| Diathermy vaporisation + TURP repeated once if necessary | 418 264 | 4551 | 921 091 | 50 | 90 576 | 0 | 0.01 | 0.04 | 0.19 | 0.5 |
| Reference strategy | ||||||||||
| TURP repeated once if necessary | 457 866 | 39 602 | 920 340 | −751 | Dominated | 0 | 0 | 0 | 0.01 | 0.01 |
QALY=quality adjusted life year; N/A=not applicable; TURP=transurethral resection of prostate.
*Excludes other strategies dominated at a willingness to pay threshold of £20 000/QALY.